Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics

Brand Names


Bulgaria: Nevanac; Czech Republic: Nevanac; Denmark: Nevanac; Estonia: Nevanac; Finland: Nevanac; Germany: Nevanac; Greece: Nevanac; Hungary: Nevanac; Ireland: Nevanac; Latvia: Nevanac; Lithuania: Nevanac; Luxembourg: Nevanac; Malta: Nevanac; Netherlands: Nevanac; Poland: Nevanac; Portugal: Nevanac; Romania: Nevanac; Slovakia: Nevanac; Slovenia: Nevanac; Sweden: Nevanac; UK: Nevanac.

North America

Canada: Nevanac; USA: Nevanac.

Latin America

Argentina: Nevanac; Mexico: Nevanac.

Drug combinations


Nepafenac: C~15~H~14~N~2~O~2~. Mw: 254.28. (1) 2-Amino-3-benzoylbenzeneacetamide; (2) 2-(2-Amino-3-benzoylphenyl)acetamide. CAS-78281-72-8 (1997).

Pharmacologic Category

EENT Preparations; Nonsteroidal Anti-inflammatory Agents. Ophthalmic Anti-inflammatory Drug. (ATC-Code: S01BC10).

Mechanism of action

Prodrug, which once converted to amfenac inhibits prostaglandin synthesis by decreasing activity of enzyme cyclooxygenase, which results in decreased formation of prostaglandin precursors.

Therapeutic use

Treatment of pain and inflammation associated with cataract surgery.

Pregnancy and lactiation implications

Teratogenic events not observed in animal studies. Safety and efficacy in pregnant women not established. Exposure to NSAIDs late in pregnancy may lead to premature closure of ductus arteriosus. Excretion in breast milk unknown (use with caution in nursing women).

Unlabeled use


Hypersensitivity to nepafenac, other NSAIDs, or any component of the formulation.

Warnings and precautions

Use with caution in previous sensitivity to acetylsalicylic acid and phenylacetic acid derivatives, including patients who experience bronchospasm, asthma, rhinitis, or urticaria following NSAIDs or aspirin. May cause keratitis; continued use in keratitis may cause severe corneal adverse reactions, potentially resulting in loss of vision. Use with caution in predisposition to bleeding (bleeding tendencies or medications which interfere with coagulation), in diabetes mellitus (may be at risk of corneal adverse events, potentially resulting in loss of vision), in complicated ocular surgeries, corneal denervation, corneal epithelial defects, ocular surface disease, or repeat ocular surgeries (within a short timeframe)(may be at risk of corneal adverse events, potentially resulting in loss of vision), and in rheumatoid arthritis. May slow or delay healing or prolong bleeding time following surgery. Use for more than 1 day prior to surgery or for 14 days beyond surgery may increase risk and severity of corneal adverse events. Patients using ophthalmic drops should not wear soft contact lenses.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart